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The economic burden of tuberculosis and latent tuberculosis in People Living with HIV 
in Brazil: a cost study from the patient perspective.  
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Introduction 
The economic consequences of the vicious cycle of tuberculosis (TB) and poverty in low and 
middle income countries is well known. It is estimated that tuberculosis consumes about $ 12 
billion of the income of the world's poorest communities every year. Furthermore, TB patients 
can lose three to four months of work time and the loss of earnings can achieve up to 30% of 
the annual household income1. This scenario can be even worse for people living with HIV 
(PLHIV) co-infected with TB. Patients with concurrent diseases can face financial hardship 
during their diagnosis and treatment. In addition, financial hardship could lead to worse 
outcomes, such as treatment abandonment and death2.  
The World Health Organisation (WHO) has recommended cost studies as a way to support 
strategies aiming the end of catastrophic health expenditures due to TB by 2020 2. Brazil is one 
of the 30 countries with the highest TB/HIV burden worldwide, and is committed to the goals 
stated by the WHO and its 2017 National Plan entitled “Brazil free of TB”. The plan aims to 
reduce TB incidence and mortality rates to less than 10 cases/100,000 inhabitants and less than 
one death/100,000 inhabitants, respectively, by 2035. Another goal is to reduce to zero the 
number of families facing catastrophic cost due to TB by 2020 3. However, there is a lack of 
information in the literature addressing costs for TB and Latent TB/HIV (LTB/HIV) co-
infection in the country, especially from the patient perspective. 
The objective of this study is to evaluate the direct and indirect costs of TB/HIV and LTB/HIV 
co-infection from the patient perspective from pre-diagnosis to treatment period. This study is 
the first investigation of patients’ costs involving co-infection in Brazil. 
 
Methods 
Study location 
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The study was conducted in the city of Recife, capital of the state of Pernambuco, Brazil.  The 
data collection was conducted in a referral service for PLHIV, Correia Picanco Hospital (CPH), 
which provides care for about 60% of all individuals with HIV/AIDS in the state.  
Sample size calculation 
The costing study was conducted alongside a pragmatic clinical trial, designed to evaluate the 
effectiveness and cost-effectiveness of a protocol for TB diagnosis in PLHIV. The sample size 
for the epidemiological study was calculated using the mortality rate estimated by a cohort 
study of TB/HIV co-infected patients treated in CPH 4. The sample size was determined using 
the following parameters: (1) mortality rate of 20% in one year (80% survival rate in 400 days); 
(2) study power of 80%; (3) Alpha error of 5%; (4) Relative Risk (RR) of 0.5 comparing the 
rate in both groups, reduction of 50% (assumption). The hypothesis was that the intervention 
arm would detect more TB cases and have a lower mortality rate when compared with the 
routine arm. Thus, a proportion of 2:1 patients in the intervention:routine arms was applied to 
obtain a smaller confidence interval. The total sample size was 483 HIV positive patients (322 
in the intervention group and 161 in the routine group). We used data from the first year of the 
trial to conduct the costing study. 
Study population, inclusion and exclusion criteria 
We followed the same exclusion and inclusion criteria established for the clinical trial. We 
included adult participants with HIV positive status recruited for the epidemiological study, 
who developed TB or performed isoniazid preventive therapy (IPT) during the first year of the 
trial. Participants were excluded if they were in TB treatment at the research enrolment or had 
been treated in the previous three months. We also excluded patients who had started 
antiretroviral therapy (ART) before their first visit to CPH, those registered only to collect ART 
and those transferred to another health service during the study period. 
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Study procedures 
HIV positive patients had a first appointment with a nurse to collect data for the 
epidemiological study. Patients were followed-up for one year and those diagnosed with TB 
co-infection, active TB or LTB, were invited to take part in the costing study. TB diagnosis 
was established through a screening by clinical algorithm, clinical assessment and confirmatory 
tests (gene Xpert, sputum smear microscopy and chest X-ray) for patients in the intervention 
arm, or through clinical assessment and sputum smear microscopy and chest X-ray for patients 
in the routine arm.  IPT was provided for LTB/HIV patients with tuberculin skin test (TST) 
higher than 5 mm or for those who had contact with TB patients.  
We followed all patient’s pathway during the pre-diagnosis period (retrospectively) and 
treatment period (prospectively). Pre-diagnosis was the period between the onset of TB 
symptoms until TB/LTB diagnosis. The treatment period was the time from the beginning of 
the treatment until cure, death or treatment abandonment. We considered loss of follow-up 
those patients who did not attend ambulatory appointments at CPH for six months after starting 
the treatment.  
Questionnaire to collect patients’ costs 
A standardised questionnaire based on “The tool to estimate patient cost” was applied to collect 
data about out-off-pocket expenses (direct medical and non-medical costs) and indirect cost 5. 
The questionnaire covered demographic and socio-economic data; TB characteristics (first 
symptoms, diagnostics tests, type of TB); type of health care (inpatient, outpatient and 
emergency care); direct costs (transport, food, caregiver, drugs, tests); indirect costs (income 
and time loss travelling to the hospital for appointments, tests and to collect drugs, waiting and 
consultation time, inpatient care). Trained nurse technician conducted the interviews after 
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every patient appointment at the CPH. Parents or careers of infirm patients were asked to 
complete the questionnaire on their behalf, if necessary.  
Direct medical and non-medical costs were referred by patients during the interviews. Indirect 
costs - income and time loss - was also reported by patients. For those patients who were on 
sickness benefit due to TB/HIV, income loss was calculated as the difference between an 
employee’s wages forgone and the sickness benefit received 6. The monetary value of the time 
loss was calculated based on the Brazilian minimum wage/2015 (monthly: US$ 273.95; daily: 
US$ 9.13; hourly: US$ 1.31) 7. All costs were calculated in local currency (Brazilian Real, 
2015 prices) and converted to US dollars using an average exchange rate for the period of study 
as calculated by OANDA (R$1= US$0.34765). 
Data analysis 
Questionnaires were double entered in a virtual platform hosted by Fundacao Oswaldo Cruz 
(FIOCRUZ-PE - patient costs). Data analysis were undertaken in Stata/IC 14. The primary 
outcome was mean costs per TB/HIV and LTB/HIV patient. We calculated the costs by disease 
category and period of analysis (pre-diagnosis and treatment period). To test difference in 
proportions, we used Fisher’s exact. We applied Wilcoxon-Mann-Whitney test for non-
parametric distribution to check differences in mean and total costs between TB/HIV and 
LTB/HIV groups. All p-values below 0.05 were considered statistically significant.  
 
Results 
Among 239 PLHIV recruited in the first year of the trial, 31 patients were included into the 
costing study: 26 patients who were diagnosed and treated for TB/HIV and five who were given 
IPT. No major differences between patients being treated by TB/IV and patients under 
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LTB/HIV treatment were observed, apart from difference in gender: in the TB/HIV category, 
the majority of patients were male, whilst most of LTB/HIV patients were female (p = 0.005). 
The age group of 18-39 years old was more frequent and more than 50% of the patients had a 
monthly income lower than the Brazilian minimum wage. The majority of patients (84% of the 
total sample) had a minimum of four years of study in both groups. The proportion of smoking, 
alcohol dependence and use of illicit drugs was similar between TB/HIV and LTB/HIV groups 
(Table 1). 
TB/HIV patients were more likely to attend emergency care during both pre-diagnosis (p = 
0.001) and treatment period (p = 0.005) and being hospitalised during the treatment period (p 
= 0.027). Furthermore, TB/HIV presented lower CD4 count (<200 cells/m3) at the first 
appointment at CPH when compared with LTB/HIV patients (p = 0.013). Eight deaths occurred 
in the TB/HIV group and no death occurred in LTB/HIV group, however, the difference in 
outcomes between the groups was not statistically significant (Table 2).  
The mean cost of treatment period was higher when compared with pre-diagnosis period for 
both TB/HIV (US$ 840 vs US$ 589) and LTB/HIV (US$ 127 vs US$ 39).  TB/HIV patients 
incurred higher costs during pre-diagnosis and treatment when compared to LTB/HIV patients; 
it was almost nine times higher than the latter (US$ 1,429 vs US$ 166, p = 0.001) (Table 3). 
The main cost component for TB/HIV was indirect costs for pre-diagnosis (78%) and treatment 
periods (73%), respectively. Whilst, the higher costs for LTB/HIV were mainly on direct non-
medical costs (50%) and direct medical costs (50%) during pre-diagnosis and treatment period, 
respectively (figure 1). 
 
Discussion 
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Our results suggest that patients with TB/HIV co-infection face much higher costs than those 
being treated as LTB/HIV. In our study, TB/HIV patients incurred almost 9 times higher total 
costs than LTB/HIV (US$ 1,429 vs US$ 169). The main cost component for TB/HIV was 
indirect costs (US$ 1,071 in total), especially income loss (US$ 749). High indirect cost may 
be linked to delays in TB diagnosis and treatment, which can also lead to patient’s health state 
deteriorates and, consequently, more complications during the treatment, such as 
hospitalisations, side effects and more visits to emergency and outpatient care.  
International literature on patients costs seem to differ from the Brazilian context. In Cambodia, 
the mean indirect cost was estimated in US$ 176 and US$ 517 during the pre-diagnosis and 
treatment, respectively 8. The indirect cost varied from US$ 171 to US$ 253 during the 
treatment in Nigeria. In Ethiopia it was US$ 117 during the pre-diagnosis 9–11. These figures 
are relatively lower when compared to the Brazilian estimates. Conversely, some of these 
countries presented similar or higher direct costs when compared with Brazil. Direct costs in 
Nigeria variated from US$ 62 to US$ 379. Nigeria provides free diagnostic testing and 
treatment free of charge to all TB patients in decentralised services  11,12. Direct costs in 
Cambodia and Burkina Faso were also similar to Brazil, US$ 137 and US$ 120, respectively 
(all costs adjusted by inflation, 2015 prices). These countries also adopt free TB diagnosis and 
treatment 8,13. Lower human and infrastructure capital and variations in methodological 
approaches for cost assessment may explain the difference in results. 
Our study has some limitations; the first being the use of data from a pragmatic clinical trial. 
Some patients in the intervention group had their diagnosis earlier than those enrolled into the 
routine, what has likely reduced their cost of the treatment due to early TB diagnosis and 
reduction of complications, such as hospitalisation. However, the objective of this study was 
to give a general picture of the costs involved in TB/HIV diagnosis and care. A second 
limitation was the small size, especially for the LTB/HIV group, which had only five patients. 
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A third limitation was a potential recall bias, especially for the pre-diagnosis period. Recall 
bias also affected the measurement of costs during the treatment period if there was a long 
interval between the appointments at CPH and long-term hospitalisation in other health 
services. In a recent publication, Sweeney and colleagues (2016) mentioned recall bias as a 
significant concern in surveys aiming to estimate the impact of disease on poverty. The authors 
suggested the follow-up of a cohort along the clinical pathway 14. Our study adopted this 
strategy. The interviews were conducted at every patient appointment at CPH from the 
beginning of TB/LTB treatment until patient discharge or death. Thus, the interval between 
interviews was reduced and, consequently, memory bias was better controlled. 
Our study is the first costing study conducted from the patient perspective addressing TB/HIV 
co-infection in the country. The study is directly linked to the goal of the Brazilian National 
Plan and with the global target to end catastrophic costs due to TB for patients and families. It 
is clear that the free access to TB care is not enough to prevent patients from facing financial 
costs, especially due to indirect and direct non-medical costs. TB/HIV co-infected patients 
facing high costs can suffer worsening health outcomes, which can be a barrier to reduce TB 
deaths among PLHIV, one of the milestone of the United General Assembly, as part of the 
Sustainable Development Goals 15. Public health policies may address ways to prevent high 
patients’ costs through the introduction of more accurate algorithms for TB diagnosis in PLHIV 
to prevent delays in the diagnosis and treatment. Further studies should investigate catastrophic 
health expenditures and effect of social protection on patients costs in the Brazilian context.   
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